Tagged Articles

Sanofi 40 articles

Several companies named in Taxotere side effects lawsuit

Several companies who had a hand in the chemotherapy drug Taxotere were hit by a lawsuit filed by several people for alleged breach of implied warranty, design defect and product liability. They allege the breast cancer treatment caused them to permanently lose their hair. The lawsuit, filed in Cook County Circuit Court, names Sanofi U.S. Services Inc.; Winthrop U.S.; Hospira Worldwide LLC; McKesson Packaging; Sandoz Inc.; Accord Healthcare Ltd.; and Does Inc. The lawsuit was filed by Linda and Robert Rice, Antoinette and Vernon R. Clark, Sonia and Earnest Collins, Bianca and John Conklin, Lynell and Michael Daggs, Madeleine Dwolakowski, ... Read More

Taxotere MDL maintains rapid growth, lawsuits over permanent hair loss

This summer we reported that the Taxotere federal multidistrict litigation had grown from 33 lawsuits to more than 1,000 in just a little more than seven months. Now six months later, the litigation has continued to see dramatic increase. More than another 1,000 suits have been added to the MDL, with a total of 2,304 claims as of Nov. 15, 2017, according to the United States Judicial Panel on Multidistrict Litigation. MDL -2740 Taxotere (Docetaxel) Products Liability Litigation under U.S. District Judge Kurt D. Engelhardt was established in the Eastern District of Louisiana in October of last year. The federal ... Read More

FDA approves cooling caps for more cancer patients

Since 2015, breast cancer patients have had FDA-approved access to the DigniCap Cooling System, which helps to reduce the occurrence and severity of the side effect of hair loss associated with chemotherapy. This was the same year that women began to learn that Taxotere, a drug often included in breast cancer treatment, could cause not only temporary, but permanent alopecia, or hair loss. In 2015 the U.S. Food and Drug Administration required Taxotere’s manufacturer, Sanofi-Aventis, to add the warning of this risk to the drug’s label. The label change and awareness that arose with litigation against Sanofi has allowed women the ... Read More

Taxotere Plaintiffs call for Sanofi sanctions

The National Law Journal reports that plaintiffs’ attorneys in the federal Taxotere multidistrict litigation (MDL) in Louisiana, which as of May 15 included more than 1,000 lawsuits, filed a motion on May 30 saying that Sanofi should be sanctioned for a motion it filed in April. Sanctions are penalties or other means of enforcement imposed by judges for violation of a court rule, meant to provide incentives for obedience with the law and to maintain both order and fairness in court. Sanofi attorneys asked a federal judge to look into possible third-party funding of the litigation, which accuses the company ... Read More

More than 1,000 suits in Taxotere MDL

In October last year, the MDL-2740 Taxotere (docetaxel) Products Liability Litigation was formed when 33 lawsuits that had been filed federally against drugmaker Sanofi SA were consolidated in the Eastern District of Louisiana under Judge Kurt D. Engelhardt. Now just a little more than seven months later, the number of suits in the multidistrict litigation (MDL) has grown to 1,006 as of the May 15 update from the Judicial Panel on Multidistrict Litigation (JPML). All of the suits in the MDL allege that chemotherapy drug docetaxel can cause permanent hair loss when other competing drugs do not carry this risk ... Read More

French families sue Sanofi alleging epilepsy drug causes birth defects

A group of French families are suing Sanofi alleging the pharmaceutical company’s epilepsy drug Depakine caused birth defects. APESAC, the association assisting parents of children suffering from “foetal anti-convulsant syndrome,” raised concerns in 2014 about being slow to act on the drug’s harm to developing fetuses. APESAC claims the number of children affected since the anti-seizure drug hit the market in 1967 to be about 30,000. Depakine, which is sold in the U.S. by Abbott Laboratories under the brand name Depakote, contains the active ingredient sodium valproate. A Sanofi spokeswoman previously said that the company had become aware of the link ... Read More

Two federal MDLs appoint women as co-lead counsels, the legal community discusses diversity in MDL leadership

Recently the New Jersey Law Journal, The Legal Intelligencer and Law.com published articles noting that the leadership in multidistrict litigation (MDL) is traditionally dominated by men. Law.com said that Hunter Shkolnik, of New York’s Napoli Shkolnik, acknowledged a “big problem in leadership” of MDLs in general when it comes to diversity in gender and race. After the article was published, Shkolnik would be appointed to the Plaintiffs’ Steering Committee for the Taxotere (Docetaxel) Products Liability Multidistrict Litigation (MDL) in the United States District Court, Eastern District of Louisiana along with Karen Barth Menzies and Abby E. McClellan ,who were also ... Read More

FDA approves two new combination type 2 diabetes treatments

Two new treatments for type 2 diabetes were approved by the Food and Drug Administration (FDA), and both contain a combination of the same types of medications – an anti-diabetic drug from the GLP-1 receptor class, and a long-acting insulin. The approvals for both Sanofi’s LixiLan and Novo Nordisk’s IDegLira, were delayed for three months after being recommended for approval by FDA advisory panels last May. LixLan’s approval in the U.S. is its first worldwide for the combination treatment, which includes the GLP-1 receptor agonist lixisenatide (Lyxumia/Adlyxin)and the insulin glargine (Lantus). It is intended for patients with type 2 diabetes ... Read More

Counsel appointed for Taxotere MDL

On Nov. 17, 2016, the United States District Court, Eastern District of Louisiana’s Judge Kurt D. Engelhardt issued Pretrial Order No. 2, appointing two New Orleans attorneys as Plaintiffs’ Liaison Counsel and one as Defendants’ Liaison Counsel in the Taxotere (Docetaxel) Products Liability Multidistrict Litigation (MDL). Taxotere is a chemotherapy drug that is used to treat many kinds of cancers including breast, lung, prostate, stomach, and head and neck cancer. The manufacturer of the drug, Sanofi SA, is accused of illegally, untruthfully marketing Taxotere as superior to similar competing drugs, while concealing from American consumers that the drug caused permanent ... Read More

Chemo drug Taxotere MDL leadership to be chosen

Texas Lawyer reports that there were more than 40 applications filed for lead roles in the Taxotere liability multidistrict litigation (MDL) and last week Louisiana Eastern District Chief Judge Kurt Engelhardt was scheduled to name the lead counsel. Taxotere is a chemotherapy drug used to treat breast, lung, prostate, stomach, and head and neck cancer. The pharmaceutical company Sonafi SA is accused of illegally, untruthfully marketing its cancer drug Taxotere as superior to similar competing drugs, while concealing that the drug caused permanent hair loss. According to Texas Lawyer, almost 200 cases have already been filed specifically by breast cancer ... Read More